Skip to main content

Advertisement

SpringerLink
Log in

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m2 for metastatic breast cancer (MBC) in patients previously treated with anthracyclines or taxanes in routine clinical practice.

Materials and methods

Fifty-five patients were enrolled in a prospective multicentre study conducted in Spain. Women ≥ 18 years of age with locally advanced breast cancer who were not candidates for surgical treatment with a radical intention or patients with stage IV disease, and who had received a prior taxane or anthracycline regimen were eligible for participation.

Results

Median age was 67 years. Median progression-free survival was 3.7 months (95% CI 2.5–4.9), median overall survival 10 months (95% CI 6.6–13.5), and overall response rate and clinical benefit rate were 29.1% and 49.1%, respectively. Main grade 3 and 4 toxicities were neutropenia 9.1%, febrile neutropenia 3.6% and constipation 3.6%. In total, 86% of the patients received complete treatment without delays or dose reduction. Moreover, HER2-positive patients who received oral vinorelbine concomitantly with trastuzumab showed better response (complete response: HER2-positive 14.3% vs. HER2-negative 0%; partial response: HER2-positive 42.9% vs. HER2-negative 25.6%; p = 0.008), better disease control rate (HER2-positive 100% vs. HER2-negative 46.2%; p = 0.011), and better values for the remaining analysed variables than HER2-negative patients.

Conclusion

Our study provides real-world data on the use of oral weekly vinorelbine, which proves an effective and well-tolerated regimen for MBC patients previously treated with taxanes or anthracyclines. Patients with HER2-positive disease could also benefit from this treatment in combination with trastuzumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, et al. The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018;167(3):703–8. https://doi.org/10.1007/s10549-017-4556-2.

    Article  CAS  PubMed  Google Scholar 

  2. Fedele P, Ciccarese M, Surico G, Cinieri S. An update on first line therapies for metastatic breast cancer. Expert Opin Pharmacother. 2018;19(3):243–52. https://doi.org/10.1080/14656566.2018.1425680.

    Article  CAS  PubMed  Google Scholar 

  3. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.

    Article  CAS  PubMed  Google Scholar 

  4. Cancer B. Fact sheet. 2016. http://www.moph.gov.lb/Campaigns/Materials/FactSheet.pdf. Accessed 07 May 2018.

  5. Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, et al. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol. 2011;22(3):603–8. https://doi.org/10.1093/annonc/mdq409.

    Article  CAS  PubMed  Google Scholar 

  6. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology V. 1. 2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.

  7. Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(10):561–74. https://doi.org/10.1038/nrclinonc.2010.122.

    Article  CAS  PubMed  Google Scholar 

  8. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, et al. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol (Northwood, London, England). 2017;34(7):119. https://doi.org/10.1007/s12032-017-0975-5.

    Article  CAS  Google Scholar 

  9. Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol. 1989;16(2 Suppl 4):2–4.

    CAS  PubMed  Google Scholar 

  10. Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990;46(2):262–6.

    Article  CAS  PubMed  Google Scholar 

  11. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11(7):1245–52.

    Article  CAS  PubMed  Google Scholar 

  12. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994;5(9):854–7.

    Article  CAS  PubMed  Google Scholar 

  13. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15(1):110–5.

    Article  CAS  PubMed  Google Scholar 

  14. Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol. 2001;12(12):1677–81.

    Article  CAS  PubMed  Google Scholar 

  15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.

    Article  CAS  PubMed  Google Scholar 

  16. Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev. 2012;38(2):120–6. https://doi.org/10.1016/j.ctrv.2011.05.005.

    Article  CAS  PubMed  Google Scholar 

  17. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21(1):35–40. https://doi.org/10.1200/jco.2003.09.057.

    Article  CAS  PubMed  Google Scholar 

  18. Trillet-Lenoir V, Sommer H, Delozier T, Koralewski P, Ruiz Simon A, Lichinister M, et al. Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer. 2004;2(3):137 (Supplement).

    Article  Google Scholar 

  19. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol. 2006;57(5):554–8. https://doi.org/10.1007/s00280-005-0092-6.

    Article  CAS  PubMed  Google Scholar 

  20. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006;17(4):623–9. https://doi.org/10.1093/annonc/mdj130.

    Article  CAS  PubMed  Google Scholar 

  21. Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, et al. Single-agent oral vinorelbine as first-line chemotherapy for endocrine-pretreated breast cancer with bone metastases and no visceral involvement: NORBREAST-228 Phase II Study. Clin Breast Cancer. 2018;18(1):e41–7. https://doi.org/10.1016/j.clbc.2017.05.012.

    Article  CAS  PubMed  Google Scholar 

  22. Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, et al. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3):501–9. https://doi.org/10.1007/s10549-016-4009-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, et al. Taxanes plus trastuzumab compared to oral vinorelbine plus trastuzumab in HER2-overexpressing metastatic breast cancer. Breast care (Basel, Switzerland). 2014;9(5):344–8. https://doi.org/10.1159/000368330.

    Article  Google Scholar 

  24. Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, et al. A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Jpn J Clin Oncol. 2018;48(3):242–7. https://doi.org/10.1093/jjco/hyx188.

    Article  PubMed  Google Scholar 

  25. Farhat F, Kattan JG, Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Cancer Chemother Pharmacol. 2016;77(5):1069–77. https://doi.org/10.1007/s00280-016-3027-5.

    Article  CAS  PubMed  Google Scholar 

  26. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264–71. https://doi.org/10.1200/JCO.2010.30.8213.

    Article  CAS  PubMed  Google Scholar 

  27. Mansour M, Mourad C. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. Cancer Chemother Pharmacol. 2013;72(2):429–35. https://doi.org/10.1007/s00280-013-2216-8.

    Article  CAS  PubMed  Google Scholar 

  28. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62(1):85–91. https://doi.org/10.1016/j.lungcan.2008.02.009.

    Article  PubMed  Google Scholar 

  29. Barni S, Freier B, Garau I, Mouysset JL, Sediva M, Zamagni C, et al. Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous. Curr Med Res Opin. 2016;32(11):1807–12. https://doi.org/10.1080/03007995.2016.1211518.

    Article  CAS  PubMed  Google Scholar 

  30. Welt A, Meldgaard P, Martoni A, Hansen O, Gebbia V, Fischer von Weikersthal L, et al. Improving chemotherapy capacity by switching from IV to oral vinorelbine. Eur J Oncol Pharm. 2010;4(3):14–8.

    Google Scholar 

Download references

Acknowledgements

This study was funded by Laboratoires Pierre Fabre. Medical writing support was provided by Dr. Almudena Fuster-Matanzo of Medical Statistics Consulting S.L. (Valencia). The authors would like to give special thanks to the patients and their families.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Hospital San Cecilio, Av. De la Investigación s/n, 18016, Granada, Spain

    I. Blancas

  2. Department of Medical Oncology, University Hospital Arnau de Vilanova, Lleida, Spain

    E. Aguirre & S. Morales

  3. Department of Medical Oncology, University Hospital Arrixaca, Murcia, Spain

    M. L. Gonzálvez

  4. Department of Medical Oncology, Hospital Del Mar, Barcelona, Spain

    S. Servitja

  5. Department of Medical Oncology, University Hospital San Juan de Alicante, Alicante, Spain

    N. Díaz

  6. Department of Medical Oncology, Institut Català d’Oncologia, Girona, Spain

    S. del Barco

  7. Department of Medical Oncology, University Hospital Sant Pau, Barcelona, Spain

    A. Barnadas

  8. Department of Medical Oncology, Institut Català d’Oncologia, Badalona, Spain

    M. Margelí

  9. Department of Medical Oncology, Virgen de La Salud Hospital, Toledo, Spain

    I. García Carbonero

  10. Department of Medical Oncology, Arnau de Vilanova Hospital, Valencia, Spain

    A. Llombart

Authors
  1. I. Blancas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. L. Gonzálvez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Servitja
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. del Barco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Margelí
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. I. García Carbonero
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Llombart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Blancas.

Ethics declarations

Conflict of interest

The authors had no conflict of interest in this study.

Ethical approval

The protocol of this trial and informed consent were approved by the ethics committee of each participating hospital and met the ethical principles stated in the Declaration of Helsinki. This study was classified by the Spanish Agency of Medicines and Health Products (AEMPS).

Informed consent

Written informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blancas, I., Aguirre, E., Morales, S. et al. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clin Transl Oncol 21, 459–466 (2019). https://doi.org/10.1007/s12094-018-1946-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1946-9

Keywords

Search

Navigation